Table 3. Resistance profiles and outcomes for patients with S. aureus sepsis.
| Organism | CRO | CTX | Outcome | AmC | CIP | GM | SXT | CC | E | Va |
|---|---|---|---|---|---|---|---|---|---|---|
| S. aureus | S | S | Discharged | S | S | S | I | I | I | I |
| S. aureus | S | S | Discharged | S | S | S | S | S | S | S |
| S. aureus | S | S | Discharged | S | S | S | I | S | S | S |
| S. aureus | S | S | Discharged | S | S | S | R | S | S | S |
| S. aureus | S | S | Died | S | S | S | S | S | S | S |
| S. aureus | I | S | Discharged | S | S | I | R | S | S | S |
| S. aureus | R | I | Discharged | S | S | S | R | R | S | S |
CRO, Ceftriaxone; CTX, Cefotaxime; AmC, Amoxicillin + Clavulanic acid; CIP, Ciprofloxacin; GM, Gentamycin; SXT, Sulfamethoxazole + Trimethoprim (Co-trimoxazole); CC, Clindamycin; E, Erythromycin; Va, Vancomycin